Compare NPWR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NPWR | ENGN |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.0M | 117.2M |
| IPO Year | 2021 | 2023 |
| Metric | NPWR | ENGN |
|---|---|---|
| Price | $1.23 | $1.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 10 |
| Target Price | $2.85 | ★ $3.29 |
| AVG Volume (30 Days) | 519.2K | ★ 724.6K |
| Earning Date | 11-12-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $1.40 |
| 52 Week High | $5.20 | $12.25 |
| Indicator | NPWR | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 25.91 | 38.18 |
| Support Level | N/A | $1.67 |
| Resistance Level | $1.84 | $1.84 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 1.45 | 0.00 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. Its business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. The company has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.